Lyra Therapeutics Income Statement (2021-2025) | LYRA

1Y3Y5Y7Y10YAll
Download Data
Income Statement Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Revenue & cost
Revenue 0.01M0.27M0.47M0.53M0.36M0.01M0.41M0.46M0.54M0.15M0.53M0.60M0.20M-1.32M0.18M0.18M0.03M
Operating items
Research & Development 4.77M7.50M7.08M10.34M8.51M10.79M10.05M9.45M12.60M10.80M12.37M12.27M18.24M13.26M5.90M6.36M4.88M5.11M4.05M
Selling, General & Administrative 3.06M3.56M4.02M3.57M3.89M4.13M5.14M4.40M5.13M4.57M5.00M4.36M5.82M5.14M3.93M3.61M3.26M3.50M2.24M
Restructuring Costs 6.45M2.80M1.65M0.90M0.40M-0.02M
Other Operating Expenses 1.32M1.59M24.72M-0.00M-0.01M-0.00M
Operating Expenses 7.83M11.06M11.10M13.91M12.39M14.93M15.19M15.17M17.72M16.96M17.37M16.62M24.06M49.57M12.64M11.62M9.02M9.01M6.26M
Operating Income -7.83M-11.06M-11.08M-13.64M-11.93M-14.40M-14.83M-15.15M-17.31M-16.50M-16.83M-16.48M-23.52M-48.97M-12.44M-11.41M-8.84M-8.83M-6.24M
EBIT -7.83M-11.06M-11.08M-13.64M-11.93M-14.40M-14.83M-15.15M-17.31M-16.50M-16.83M-16.48M-23.52M-48.97M-12.44M-11.41M-8.84M-8.83M-6.24M
Non-operating items
Interest & Investment Income 0.03M0.03M0.03M0.02M0.01M0.03M0.06M0.93M1.07M0.90M1.19M1.34M1.09M0.85M0.58M0.43M0.30M0.41M0.26M
Non Operating Income 0.03M0.03M0.03M0.02M0.01M0.03M0.06M0.93M1.07M0.90M1.19M1.34M1.09M0.85M0.58M0.43M0.30M1.39M0.26M
Net income details
EBT -7.80M-11.04M-11.05M-13.62M-11.91M-14.37M-14.77M-14.22M-16.24M-15.61M-15.63M-15.14M-22.44M-48.12M-11.87M-10.97M-8.54M-7.43M-5.98M
Tax Provisions 0.01M0.01M0.02M0.02M0.01M0.01M0.01M0.01M0.00M0.00M0.00M
Profit After Tax -7.80M-11.04M-11.05M-13.61M-11.91M-14.37M-14.77M-14.26M-16.25M-15.62M-15.65M-15.18M-22.45M-48.13M-11.87M-10.98M-8.55M-7.44M-5.98M
Income from Continuing Operations -7.80M-11.04M-11.05M-13.62M-11.91M-14.37M-14.77M-14.22M-16.25M-15.62M-15.65M-15.16M-22.45M-48.13M-11.87M-10.98M-8.55M-7.44M-5.98M
Consolidated Net Income -7.80M-11.04M-11.05M-13.62M-11.91M-14.37M-14.77M-14.22M-16.25M-15.62M-15.65M-15.16M-22.45M-48.13M-11.87M-10.98M-8.55M-7.44M-5.98M
Income towards Parent Company -7.80M-11.04M-11.05M-13.62M-11.91M-14.37M-14.77M-14.22M-16.25M-15.62M-15.65M-15.16M-22.45M-48.13M-11.87M-10.98M-8.55M-7.44M-5.98M
Net Income towards Common Stockholders -7.80M-11.04M-11.05M-13.62M-11.91M-14.37M-14.77M-14.22M-16.25M-15.62M-15.65M-15.16M-22.45M-48.13M-11.87M-10.98M-8.55M-7.44M-5.98M
Additional items
EPS (Basic) -0.60-0.85-0.85-1.05-0.92-0.42-0.40-0.47-0.44-0.36-0.27-0.30-0.35-36.76-9.07-0.17-0.13-5.51-3.38
EPS (Weighted Average and Diluted) -0.60-0.85-0.85-1.05-0.92-0.42-0.40-0.47-0.44-0.36-0.27-0.30-0.35-36.76-9.07-0.17-0.13-5.51-3.38
Shares Outstanding (Weighted Average) 12.95M12.99M13.00M12.99M13.01M33.95M36.83M30.24M36.83M43.68M56.95M49.80M64.01M1.31M1.31M65.11M65.76M1.35M1.77M
Shares Outstanding (Diluted Average) 12.95M12.99M13.00M12.99M13.01M33.95M36.83M30.24M36.83M43.68M56.95M49.80M64.01M1.31M1.31M65.11M65.76M1.35M1.77M
EBITDA -7.80M-11.04M-11.05M-13.62M-11.91M-14.37M-14.77M-14.22M-16.28M-15.63M-15.63M-15.12M-22.46M-48.16M-11.85M-11.00M-8.55M-7.44M-5.98M
Shares Outstanding 12.96M13.00M13.00M13.01M13.01M31.83M31.83M31.83M31.84M49.55M49.55M1.14M1.22M1.31M1.31M1.31M1.32M1.63M1.64M
Tax Rate -0.09-0.08-0.10-0.11-0.06-0.02-0.06-0.05-0.05-0.03-0.05